FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
News|Podcasts|May 13, 2024
Pfizer CentreOne Perspectives: From Exploring Sterile Injectable Capabilities to Responding to Emerging Trends
Author(s)Pfizer CentreOne
In this podcast, hear from our global experts Martin Gonzalez, PHD and Katharine Sparhawk as they share exclusive details of Pfizer CentreOne’s sterile injectable capabilities from both a technical expertise and business development point of view. Our experts will explore key topics including emerging sterile injectable trends, the company’s approach to flexibility in capacity planning and emerging trends that are shaping the development of complex biologics like ADCs.
Related to this article
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
Science, circularity, regulation, and technology are reshaping how the industry develops packaging for medicines.
Trending on Pharmaceutical Technology
1
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
2
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
3
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
4
Germany’s Medical Biotechnology Sector is Flourishing
5